tradingkey.logo

Grail Inc

GRAL
查看詳細走勢圖
100.070USD
+6.010+6.39%
收盤 02/06, 16:00美東報價延遲15分鐘
3.62B總市值
虧損本益比TTM

Grail Inc

100.070
+6.010+6.39%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+6.39%

5天

+2.30%

1月

-3.76%

6月

+202.51%

今年開始到現在

+16.92%

1年

+203.33%

查看詳細走勢圖

TradingKey Grail Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Grail Inc當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名86/392位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為105.00。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Grail Inc評分

相關信息

行業排名
86 / 392
全市場排名
212 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Grail Inc亮點

亮點風險
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
業績高增長
公司營業收入穩步增長,連續3年增長126.09%
估值低估
公司最新PE估值-9.39,處於3年歷史低位
機構減倉
最新機構持股25.81M股,環比減少20.00%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉1.72K股

分析師目標

基於 4 分析師
買入
評級
105.000
目標均價
+11.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Grail Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Grail Inc簡介

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代碼GRAL
公司Grail Inc
CEORagusa (Robert)
網址https://grail.com/
KeyAI